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Abstract— We have reached the era of full genome sequencing 
using high throughput sequencing technologies pouring out gigabases 
of reads in a day. To fully benefit from such a profusion of data high 
performance tools and systems are needed to extract the information 
lying within the sequences. This paper provides an overview of the 
evolution of high-throughput sequencing and the tools, infrastructure 
and data management developing in this space to support a key area 
in personalized medicine. The paper concludes by providing an 
outlook in the future of such technologies and their applications and 
how they might shape clinical governance.   
Keywords—high-throughput sequencing; grid; cloud; 
personalised medicine 
I. INTRODUCTION  
Technological advances of High-throughput sequencing 
(HTS) technologies over the past decade have been pivotal in 
DNA sequencing. Compared to the conventional Sanger 
sequencing approach pioneered by Edward Sanger in 1975 
using capillary electrophoresis, HTS technology provides 
massive parallel sequencing producing larger throughput at 
lower costs [1]. We are now at the stage where it is possible to 
sequence a whole human genome using a single instrument in 
26 hours [2]. There are a number of small and relatively cost 
effective, HTS platforms available including the Illumina®  
MiSeq1, Ion PGM™ (Personal Genome Machine)2 and the 
PacBio RS II3. These platforms differ in terms of protocol, 
technology, throughput and read length with the selection of 
technology dependent on application. A comprehensive 
review along with additional technological solutions can be 
found in [3] and [4].  
HTS technologies have been used in a broad range of 
applications including diagnostic testing for hereditary 
disorders, high-throughput polymorphism detections, 
                                                          
1 http://www.illumina.com/systems/miseq.html 
2https://www.thermofisher.com/uk/en/home/life-science/sequencing/next-
generation-sequencing/ion-torrent-next-generation-sequencing-workflow/ion-
torrent-next-generation-sequencing-run-sequence/ion-pgm-system-for-next-
generation-sequencing.html 
3 http://www.pacb.com/products-and-services/pacbio-systems/rsii/ 
comparative genomics, transcriptome analysis and therapeutic 
decision-making for somatic cancers [5]. The reduction in 
costs has made HTS technologies accessible to labs to perform 
high-throughput sequencing experiments, which can generate 
enormous datasets. For instance, recent advances in HTS 
technologies have resulted in instruments that are capable of 
producing >100 gigabases (Gb) of reads in a day [6]. 
Furthermore, the data generated is not noise free. For these 
reasons, coupled with the challenges of integrating 
heterogeneous datasets HTS sequencing data it is considered 
to be characterized as Big Data, and as with such examples 
there lies a significant computational challenge. High 
performance, cloud and grid computing are aspects of 
computing that have become ubiquitous with processing and 
analysis of HTS data generated at ever increasing momentum.  
With a myriad of options available it is not a 
straightforward task in selecting a computing technology to 
suit a specific HTS pipeline. To address this issue, we focus 
on the computational challenges associated with HTS and 
review how high performance, cloud and grid based systems 
can offer solutions. As part of the discussion a brief view on 
data governance will be presented with respect to HTS in 
terms of the creation, handling, security and sharing of 
sequencing data. The paper then concludes with a closing 
review of the future of HTS technology and its role in 
personalized medicine. 
II. HTS PIPELINE, APPLICATIONS AND PLATFORMS 
This technology has been applied to a diverse range of 
biological science applications including Human Genetics, 
agriculture, microbes, viruses and infectious diseases and 
Environmental Genomics. HTS platforms perform parallel 
sequencing at a large scale. This process allows the 
sequencing of millions of fragments of DNA from a single 
sample in unison. The parallel sequencing technology 
facilitates high-throughput sequencing, which allows an entire 
genome to be sequenced in about one day [2]. The scale and 
speed of these technologies are aiding the analysis of genomes 
and improving our understanding of proteins and their 
interaction with nucleic acids. HTS has been applied to varied 
 applications (Table I) from understanding the role of non-
coding sequence variants in cancer [7], identifying genomic 
targets of small molecules [8] to the reconstruction of ancient 
genomes and epigenomes [9].  
TABLE I. COMMON APPLICATIONS OF HTS TECHNOLOGY 
Application Description 
Whole 
Genome 
Sequencing 
(WGS) 
WGS can be of particular importance when the exact genetic 
cause of a disease is not fully understood. It allows for a 
more open discovery of mutations or polymorphisms. 
Furthermore, there is the potential to derive insights into 
future potential health issues. There has been recent 
investigation into how WGS could be integrated with 
clinical medicine [10]. 
Whole 
Exome 
Sequencing 
The exome comprises just over 1% of the genome but offers 
valuable information in gene discovery research. Studies 
have resulted in the identification of genes that are relevant 
to certain diseases such as inherited skin disease [11] or 
indicate conditions such as inherited autism [12]. Exome 
sequencing [13] can also be applied to identify disease-
causing mutations in pathogenic presentations where the 
exact genetic cause is unknown. 
Targeted 
Sequencing 
In cases where a suspected disease or condition has been 
identified, sequencing full genome or exome is not 
necessary. A more efficient application of HTS would be to 
use targeted sequencing of specific genes or genomic 
regions. This yields a more affordable and efficient solution 
while maintaining a high level of resolution [14].  
Chromatin 
immune-
precipitation 
sequencing  
ChiP-Sequencing is used to investigate the interactions 
between proteins and DNA [15]. It has been used to measure 
transcription binding and protein interactions. miRNA-Seq 
NGS (Next Generation Sequencing, a form of HTS) 
technology has been an enabler for analysis of 
transcriptomes [16]. 
Large-scale 
analysis of 
DNA 
methylation  
 
DNA methylation (by deep sequencing of bisulfite-treated 
DNA) acts to investigate genes epigenetic behavior. 
Whole-genome bisulfite sequencing (WGBS) combined 
with NGS and genome-wide analysis used to provide a 
comprehensive view of methylation patterns at single-base 
resolution across the genome. 
Variant 
detection 
Determining single nucleotide variants (SNVs) from NGS 
results. 
de novo 
assembly 
sequencing 
NGS alignment without a reference genome. 
Within the application area of human health, the 
application of HTS has provided evidence on the context and 
complexity of cancer genomic alterations, including point 
mutations, small insertions or deletions, copy number 
alternations and structural variations. The Cancer Genome 
Atlas (TCGA) (a coordinated project with the National Cancer 
Institute (NCI) and the National Human Genome Research 
Institute (NHGRI)) has applied HTP technologies to profile 
and analyze large numbers of human tumors to uncover the 
molecular basis of cancer. A recent study investigated the 
genomic diversity of primary prostate cancers [17].  
A number of platforms are currently used in HTS 
workflows. These platforms differ in terms of sequencing, 
imaging and output of data. Popular platforms include: Ion 
Torrent PGM™ (LifeTechnologies, Carlsbad, CA), MiSeq™ 
(Illumina, San Diego, CA) and Roche 454. The selection of 
platform is dependent upon the sequencing problem being 
investigated. A comprehensive review can be found in [14]. 
They provide a thorough summary of NGS platforms and 
applications. In particular, they also provide a synopsis of 
discoveries of cancer driver mutations achieved through NGS 
technology. 
III. HTS PLATFORM CHALLENGES  
With the complexity of genetic sequencing data, coupled with 
the inevitability of combining it with other relevant datasets so 
to obtain a complete disease profile, the outcome is highly 
technically challenging. Cloud, high performance and grid 
computing offer some answers to meeting these computational 
needs. However, there are major efforts in developing the 
computing platforms, infrastructure and data governance 
policy required to meet growth in use and need of high 
performance computing solutions. 
All platforms have their strengths and weaknesses, which 
must be considered to enable appropriate use of sequencing 
data [3]. Different HTS technologies apply different protocols, 
which in turn determine the type of data produced from each 
platform [18]. Comparing data output can be challenging in 
terms of quality scores and accuracy estimates as there is no 
quality base consensus between different manufacturers. The 
volume of HTS data is of greater magnitude than that 
generated by earlier techniques therefore analytical algorithms 
need to be optimized for speed and memory usage. In 
addition, HTS techniques produce short read data with error 
profiles that differ from previous-generation technology. This 
has resulted in the development of new algorithms to process 
short reads for sequence alignment, assembly, and read 
annotation [3]. Consensus of standardized methodologies for 
HTS analysis is still lacking [5]. 
Furthermore, using HTS platforms can necessitate 
planning for at least several hundred gigabytes of data storage 
per sample. A recent study by Baker [1], investigated the cost 
of generating sequencing data compared to the cost of storing 
this data. Interestingly, the cost of generating sequencing data 
per base is reducing much faster than the cost of data storage 
per byte. This highlights the disconnect between data 
production and data storage and the resource to process these 
data. However, compression techniques [19]–[21] could have 
the potential to help with the storage and retrieval of these 
huge data files. 
As highlighted, any HTS research in genomics will require 
significant computational resources, however, with this comes 
the need for bioinformaticians with skills to install, update, 
and run the latest tools. The skillset of the bioinformatician 
needs to be diverse as many of the stages in a typical HTS 
pipeline employ varied tools, platforms and developmental 
languages for each specific task, and much of these are open 
source supported through community forums. Furthermore, as 
also discussed, datasets themselves are complex and a 
challenge to incorporate so to best mitigate for inconsistencies 
in the creation of the datasets. Below gives a small example of 
the technologies and tools employed, a more comprehensive 
review can be found in [22]: 
 Languages: R/Bioconductor, Python, Bash, Perl. 
 Tools: BWA, samtools, vcftools, Picard, Genome 
Analysis Toolkit (GATK) [23], Bowtie, Tophat, 
Cufflinks. 
  Platforms: BIOVIA ScienceCloud [24], DNAnexus [25], 
CloVR [26]. 
IV. HIGH PERFORMANCE COMPUTING SOLUTIONS 
Each application will have a varied computational demand. 
The sections below discuss high performance computing 
solutions ranging in computational performance. 
A. Commodity Clusters 
Commodity clusters became popular in bioinformatics, 
because they offer low-budget elements and scalability with 
regard to the user’s requirements [27], [28]. Commodity 
clusters consist of regular computers (servers) which are 
connected through the network as compared to a 
supercomputer with many processors [29]. Here, a regular 
computer may also have multiple processing cores. One of the 
most well-known open-source frameworks for distributed 
computing on these clusters is Apache Hadoop [30]. Hadoop 
employs the MapReduce parallel programming framework 
which has been popularised by Google [31]. A broad 
description of this framework is as follows. It consists of the 
Map and Reduce stages, where input data is first split and 
presented as intermediate key-value pairs (mapping). Then, 
the pairs are sorted by their keys and the values are aggregated 
under their respective keys at the assigned reducer nodes [32]. 
Next the values are processed for each key (reducing), e.g. 
counting a frequency of name. 
Kawalia et al. [33] describe a workflow for exome analysis 
which incorporates the MapReduce-like components for 
parallel calculations on the commodity HPC clusters. The 
authors’ case study focuses on the clusters with a quite generic 
architecture which are shared by the researchers from the 
different disciplines, limiting their customization options. As 
in this case, it might not always be convenient to use Hadoop. 
The MapReduce concepts have been implemented in many 
other parallel solutions such as the Genome Analysis Toolkit 
(GATK) [23]; Hadoop-based set of tools, SeqPig [34]; parallel 
version of the well-known BLAST and SOM algorithms [35], 
etc. GATK framework helps the researchers to develop their 
own tools for the NGS data analysis, overcoming limitations 
of the existing problem-focused tools or complications of the 
general frameworks. This toolkit can be used for shared- or 
distributed-memory systems which enhances its applicability 
for the different types of clusters. SeqPig is a library and 
toolset, which is based on Apache Pig and aims to ease an 
analysis of sequencing data for researchers.  
The most well-known parallel programming model is 
Message Passing Interface (MPI) [36], which is often 
compared to the MapReduce paradigm [37]. Chen et al. [37] 
briefly compare the MapReduce and MPI models as discussed 
below. MPI is generally argued to be more flexible in terms of 
passing more control to the user, but at the same time this 
flexibility complicates its usage. MapReduce is often praised 
for its fault tolerance as it can re-launch a task on another node 
if one of the nodes has failed. However, the applications 
which use MPI can create check-points in order to improve 
their fault tolerance. Generally, MapReduce is considered to 
be a more suitable solution for data independent rather than 
dependent tasks as MPI allows more control over data 
communication. There are also libraries which consider both 
paradigms, MapReduce and MPI, such as MR-MPI [38]. 
Apache also offers a powerful execution engine, known as 
Spark [39], which allows the applications to perform in-
memory computations (e.g. iterative applications) which were 
traditionally disadvantaged by the MapReduce algorithm. 
Spark can be deployed on the cluster or in the cloud. 
B. GPU Computing 
Many researchers [29], [40], [41], compare Graphics 
Processor Unit (GPU)-based computing with a traditional 
CPU-based parallel computing. According to the price to 
performance ratio, parallel in nature GPUs are potentially 
more affordable and efficient as compared to sequential in 
nature CPUs [41], [40]. Hence, a GPU card can have 
thousands of cores, while more affordable workstations or 
servers usually have tens of CPU cores. A price for 
commodity GPUs also continues dropping driven by the 
expanding gaming industry [41]. In addition, one multi-core 
server or workstation takes much more space and energy than 
a GPU card with the approximately equivalent number of 
cores [42].  
NVIDIA, a well-known GPU producer, offers a platform 
and model for GPU parallel programming which is Compute 
Unified Device Architecture (CUDA) [43]. The large number 
of CUDA-compatible tools have been developed in the past 
for NGS data processing and analysis such as Cushaw [44], 
BarraCUDA [45], SOAP3 [46], CUDASW++ [47], SeqNFind 
[42], etc. A large attention has been attributed to short reads 
sequence alignment on GPUs (e.g.[44], [45]), or CPUs and 
GPUs (e.g. [47]). SeqNFind is the set of tools for sequence 
analysis which can be applied to the NGS data. As for 
statistical data (e.g. gene expression levels) analysis and 
visualisation, the open-source R-environment [48] has gained 
a wide popularity among bioinformaticians in the past years. 
Hence, the number of packages has been developed for R in 
order to enable researchers accelerate their calculations using 
CPU, such as Simple Network of Workstations (snow) [49] or 
GPU parallel computing paradigms, such as permGPU [50], 
gputools [51], etc. Although GPU computing is a promising 
direction for bioinformatics, several bottlenecks arise from the 
side of GPU memory limitations; a possibly slow data 
exchange between CPU and GPU memories [52] and the lack 
of awareness and specialised knowledge among 
bioinformaticions [40]. 
C. Cloud Computing 
Some of the first adopters of big data in cloud computing are 
users that deployed Hadoop clusters in highly scalable and 
elastic computing environments provided by vendors, such as 
IBM, Microsoft, and Amazon. Cloud-based solutions are 
increasingly offered on the market such as BIOVIA 
ScienceCloud [24], DNAnexus [25] and BaseSpace Sequence 
Hub [53]. A major advantage of these solutions is that they 
provide scalable storage and performance. Hence, there is no 
necessity to deploy and maintain the in-house resources [24], 
[25], especially, that these resources might be required to 
scale-up towards the increasing amounts of data. They also 
offer the data and project management tools which facilitate 
collaborations, regulate access to the shared data, visualise and 
analyse the data, etc. It is important to mention the big players 
in Cloud provision: Amazon Elastic Compute Cloud [54], 
 Google Genomics [55] and Microsoft Azure [56], which all 
commit to the scalability, speed and data. 
Although commercial Cloud solutions provide friendly 
interfaces and different tools for user convenience, they also 
have a few disadvantages compared to the open-source 
solutions. One of such disadvantages is a lack of flexibility on 
the public clouds as pointed out by Kwon et al. [57]. As an 
example, the authors suggest that a customization of services 
is usually limited to the provided functionality. Hence, a user 
may need to ask the cloud service provider to install additional 
software resulting in unnecessary waiting times. Another 
obvious disadvantage constitutes expenses for using a 
commercial solution [57]. There is a wide range of open-
source platforms, pipelines and other tools available to 
researchers such as the read mapping algorithm for NGS data, 
CloudBurst [58]; the platform which combines virtual 
machine (VM) and cloud technologies, CloVR [26]; the 
automated pipeline, Crossbow [59].  
However, the open-source solutions arguably require more 
time and effort from the user in order to set up and manage the 
system (e.g. CPU, memory) and the data analysis pipeline as 
compared to commercial solutions [57]. The system’s set up 
and maintenance by themselves require substantial technical 
skills [26], [60]. Furthermore, various packages / applications 
often have to be integrated with each other for the different 
pipeline’s stages [26]. More recently, some open-source 
software aims to reduce the user’s burden, e.g. CloVR claims 
that they provide the pre-configured pipelines which can be 
easily installed as a part of VM.  
V. PRIVACY AND DATA MANAGEMENT  
Beyond the major challenges in developing and employing 
high performance computing platforms and infrastructures, 
there lies the critical area of data management and 
governance. Sequencing the human genome has led to 
challenges in how such huge datasets are created, handled, 
integrated, stored and shared. These challenges have been 
exacerbated by the increased complexity and size from HTS. 
Coupled with the inevitability of translational bioinformatics 
in which heterogeneous datasets are combined so to obtain a 
complete disease profile, the outcome becomes even more 
demanding. This section will discuss some of the key data 
privacy and management challenges that are encountered 
when gathering, sharing and analyzing such large repositories, 
and how cloud computing platforms among other solutions are 
addressing these concerns.  
Existing data governance mechanisms (Table II) enable the 
relatively free sharing of de-identified data. Such mechanisms 
have guided genomic data sharing policies including the 
National Human Genome Research Institute (NHGRI) 
established the Electronic MEdical Records and GEnomics 
(eMERGE) Consortium to investigate the best approaches to 
achieve this [61]. The study by Reid et al. [62] provides a 
good overview of the challenges faced by the sheer 
translational nature of modern genomic data. In such cases to 
enable a complete overview of the many compounding factors 
that influence disease progression additional potentially 
identifiable data may need to be included. [63]. At this point 
the data may become traceable back to the subject and thus 
becomes protected health information (PHI) which is subject 
to a high degree of handling, storage and security compliance. 
TABLE II. US AND EU ORGANIZATIONS ESTABLISHED  
FOR THE PROTECTION OF HEALTH AND PERSONAL DATA 
Legislation Date Description 
Health Insurance 
Portability and 
Accountability Act  
(HIPPA) 
 
Health 
Information 
Technology for 
Economic and 
Clinical Health  
Act (HITECH) 
 
 
1996 
 
 
 
 
 
 
2009 
HIPPA safeguards individuals’ protected 
health information (PHI) [64]. Its privacy 
rules set guidelines on how health data 
can be disseminated through suitable de-
identification. Two standards, (Safe 
Harbor and Expert Determination) may 
be used for the de-identification process 
[65].  
HIPAA was later supplemented by the 
Health Information Technology for 
Economic and Clinical Health Act 
(HITECH). 
Directive 
95/46/EC of the 
European 
Parliament and 
Council of the 
European Union 
(EU) 
Directive (EU) 
2016/680 
Regulation (EU) 
2016/679/  
 
 
 
 
1995 
 
 
With 
effect 
from 
2018 
This directive covers the protection of 
individuals with regard to the processing 
of personal data and on the free 
movement of such data. (Official Journal 
of the European Union L 281: 0031–
0050.) This will be repealed and replaced 
by the regulation and directive on the 
protection of natural persons with regard 
to the processing of personal data [66]. 
In terms of computational promise cloud-based solutions 
have many advantages, however there are still a challenges in 
respect of the security and privacy of the sensitive personal 
data uploaded to the clouds or other external sources [1], [67]. 
Hence, the researchers explore private clouds (e.g. in-house 
clouds) as well as a mixture of private and public clouds for 
the different data types [1]. Bendekgey [68] raises the point 
that looking back over the data breaches reported to the US 
government since 2009 that the fear of storing data on the 
cloud has been misplaced, highlighting that cloud based 
systems should be tailored to meet the high security demands 
for storing genomic PHI. In turn, the cloud-service providers 
put emphasis on their safety and privacy measures for the 
sensitive personal data which might include data encryption, a 
customisable level of data access, compliance with the health 
and clinical related data regulations. Amazon Web Services 
(AWS)4 offers a suite of cloud computing solutions that 
endeavor to meet the stringent privacy and security rules, 
requirements for auditing, back-ups, and disaster recovery, 
established by the HIPAA among other certifications. The 
AWS DNAnexus [25] platform is one such example with the 
appropriate clinical and data governance certification. Some 
HTS-oriented platforms such as BC Platforms [69] can also be 
deployed in-house which might be an appealing solution in 
terms of security, cost and application. While Microsoft Azure 
[70] has moved to offer the option of a hybrid cloud 
combining both private and public clouds if necessary. 
VI. FUTURE 
An important challenge in the Bioinformatics and Biomedical 
domain is bridging the gap between genomic and proteomic 
data production and the analytics required for the 
                                                          
4 https://aws.amazon.com/compliance/ 
 understanding of functional biology. Many countries are 
recognizing this challenge and are developing plans to 
integrate genomic and patient data to deliver personalized 
medicine and personal genomics. Such initiatives include the 
Genomics England led 100,000 Genome Project to sequence 
100,000 of the genomes of UK patients and integrate with 
patient data, led by Genomics England. The PatientsLikeMe 
project aims to support the sharing of data and have shared 
agreements with the FDA and pharmaceutical agencies such 
as AstraZeneca. With the variety of high-throughput 
technologies, including transcriptomics using microarrays, 
genome-wide association studies (GWAS), metabolomics 
modeling, Yeast 2 Hybrid (Y2H) assays, proteomics, high-
throughput chemistry screening and in-silico techniques. HTS 
is one piece in the Bioinformatics knowledge base but it has 
the potential to augment or complement these existing 
technologies. Integration of these diverse data in a clinical 
setting to understand disease is not without its challenges. The 
study by Xuan et al. [14] highlighted that whole genome 
sequencing can identify genomic variations between patients 
with a disease and without a disease, however moving to 
uncovering clinical useful information and validating 
genotype-phenotype. Translation of relevant prognostic 
markers identified by high-throughput techniques into clinical 
tools for personalized patient treatment has been slow due to 
issues such as the reproducibility and validity of findings 
across studies, unfocused study design and inappropriate 
selection and application of statistical techniques [71], [72]. 
What is required are standardized pipelines from sequencing 
until analysis are capable of generating reliable analytical 
results. To this end there are a number of standardization 
initiatives such as the Sequencing Quality Control (SEQC) 
project, a community-wide collaborative led by FDA and the 
HUPO Proteomics Standards Initiative. Interestingly, we can 
see that the next wave of sequencing technologies are moving 
away from high-throughput to small scale real time 
sequencing. Such devices include Oxford Nanopore’s 
MinION, DNA sequencing sensors to integrate with devices 
for more bounded tasks such as pathogens surveillance [73]. 
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